BETA: Please send your feedback!
Sarepta Therapeutics
SRPT:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
About
Biotechnology
Founded 1980
Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. It focuses on the development of its potentially disease-modifying DMD drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
website
Headquarters
Executives
| Name | Title | Gender |
| Edward M. Kaye, MD | President & Director | Male |
| TY Howton, Jr. | Secretary, Senior Vice President & General Counsel | Male |
| M. Kathleen Behrens, PhD | Chairman | Female |
| Sandesh Mahatme | Executive VP, Chief Financial & Business Officer | Male |
| Ian Estepan | Head-Investor & Media Relations | Male |
| Diane Berry, PhD | VP-Global Health Policy & Government Affairs | Female |
| Joan Wood | Vice President & Head-Human Resources | Female |
| Shamim Ruff | Senior Vice President-Regulatory Affairs & Quality | Female |
| Catherine Stehman Breen, MD | Chief Medical Officer | null |
Mindful Investing Summary
Sarepta Therapeutics - Competitors and Related Companies
How Sarepta Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Sarepta Therapeutics
SRPT:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
BioCryst Pharmaceuticals
BCRX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
NewLink Genetics
NLNK:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
PTC Therapeutics
PTCT:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
Retrophin
RTRX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
Gilead Sciences
GILD:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2020
—